Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT05018520

PHASE3

The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk

Sponsor: Ruijin Hospital

View on ClinicalTrials.gov

Summary

The Safety and Effectiveness of Four Courses of R-CHOP Plus Four Courses of Rituximab Versus Six Courses of R-CHOP Plus Two Courses of Rituximab in the Treatment of Naive, Low-risk, Non-mass Diffuse Large B-cell Lymphoma: a Multi-center, Prospective, Randomized Controlled Study

Official title: The Safety and Effectiveness of Four Courses of R-CHOP Plus Four Courses of Rituximab Versus Six Courses of R-CHOP Plus Two Courses of Rituximab in the Treatment of Naive, Low-risk, Non-mass Diffuse Large B-cell Lymphoma: a Multi-center, Prospective, Randomized Controlled Study

Key Details

Gender

All

Age Range

14 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

640

Start Date

2021-09-17

Completion Date

2028-06-30

Last Updated

2026-05-11

Healthy Volunteers

Conditions

Diffuse Large B Cell Lymphoma

Interventions

DRUG

Six Courses of R-CHOP Plus Two Courses of Rituximab

The patients will be given RCHOP (Rituximab 375mg/m2 ivgtt, D0, Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1, Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses) followed by Rituximab (375mg/m2 d1, every 21 days for total 2 courses)

DRUG

Four Courses of R-CHOP Plus Four Courses of Rituximab

The patients will be given RCHOP (Rituximab 375mg/m2 ivgtt, D0, Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1, Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 4 courses) followed by Rituximab (375mg/m2 d1, every 21 days for total 4 courses)

Inclusion Criteria: * Pathologically confirmed CD20 positive DLBCL based on 2016 WHO classification who achieved CR after 4 cycles of RCHOP therapy (examined by PET-CT, Deauville score 1-2) * Treatment naïve * IPI=0,1 * Age ≥ 14 or ≤75 years * non-mass (The length of the lesion\<7.5cm) * ECOG=0,1 * Life expectancy\>6 months * Informed consented Exclusion Criteria: * Have received systemic or local treatment including chemotherapy in the past * Have received autologous stem cell transplantation in the past * Past medical history of other malignant tumors, except basal cell carcinoma of the skin and cervical cancer in situ * Accompanied by uncontrolled cardiovascular and cerebrovascular diseases, coagulopathy, connective tissue diseases, severe infectious diseases and other diseases * Primary skin, primary central nervous system lymphoma * Left ventricular ejection fraction ≦50% * Other concurrent and uncontrolled situation which will affect the patient's medical status based on researchers decision * Laboratory test value during screening: (unless it is caused by lymphoma) Neutrophils \<1.5\*109/L Platelet\<80\*109/L Hemoglobin \<100g/L ALT or AST is 2 times higher than the upper limit of normal, AKP and bilirubin are 1.5 times higher than the upper limit of normal E. Creatinine level is higher than 1.5 times the upper limit of normal * Psychiatric patients or other patients who are known or suspected to be unable to fully accomplish with the research protocol * Pregnant or lactating women * Patients with positive HbsAg test results need to undergo HBV-DNA test and can be admitted to the group after turning negative. In addition, if the HBsAg test result is negative, but the HBcAb test is positive (regardless of the HBsAb status), HBV-DNA is also required；if the result is positive, patients also need to be treated to become negative before entering the group * Patients living with HIV * Patients with TP53 mutations or those who have not undergone DLBCL hot spot gene screening

Locations (1)

Ruijin Hospital

Shanghai, Shanghai Municipality, China